Company Profile

Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, Windlas Biotech has informed that the officials of the Company will be attending the meeting with an Investor/Analyst at the Dehradun Plant on Friday, May 03, 2024. Discussions will be based on publicly available information. 

The above information is a part of company’s filings submitted to BSE.

Windlas Biotech is currently trading at Rs. 562.85, up by 12.90 points or 2.35% from its previous closing of Rs. 549.95 on the BSE.

The scrip opened at Rs. 550.00 and has touched a high and low of Rs. 569.00 and Rs. 550.00 respectively. So far 2242 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 590.00 on 01-Mar-2024 and a 52 week low of Rs. 226.40 on 06-Apr-2023.

Last one week high and low of the scrip stood at Rs. 569.00 and Rs. 508.45 respectively. The current market cap of the company is Rs. 1143.82 crore.

The promoters holding in the company stood at 62.82%, while Institutions and Non-Institutions held 13.06% and 24.12% respectively.

Windlas Biotech has commissioned its state-of-the-art injectable facility for manufacturing of Small Volume Parenteral products, built to meet international cGMP standards. The company has received manufacturing license from the Drug Controlling & Licensing Authority of Uttarakhand after joint inspection conducted by Central Drugs Standard Control Organisation and State Licensing Authority of Uttarakhand. 

The facility has initiated manufacturing of commercial batches and it expects to introduce several new products over the course of Financial Year 2025. This milestone marks company’s continued foray in development and manufacturing of complex dosage forms like Ampoules, Liquid Vials and Lyophilized Vials thereby extending its product portfolio to critical care and other specialized therapeutic segments. This Injectable plant shall cater to all three of its business verticals: CDMO, Trade Generics & Institutional, and Exports. 

Windlas Biotech provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world.

Windlas Biotech has commissioned its state-of-the-art injectable facility for manufacturing of Small Volume Parenteral products, built to meet international cGMP standards. The company has received manufacturing license from the Drug Controlling & Licensing Authority of Uttarakhand after joint inspection conducted by Central Drugs Standard Control Organisation and State Licensing Authority of Uttarakhand. 

The facility has initiated manufacturing of commercial batches and it expects to introduce several new products over the course of Financial Year 2025. This milestone marks company’s continued foray in development and manufacturing of complex dosage forms like Ampoules, Liquid Vials and Lyophilized Vials thereby extending its product portfolio to critical care and other specialized therapeutic segments. This Injectable plant shall cater to all three of its business verticals: CDMO, Trade Generics & Institutional, and Exports. 

Windlas Biotech provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world.